Compare PLAB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | GHRS |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1995 | 2021 |
| Metric | PLAB | GHRS |
|---|---|---|
| Price | $27.16 | $27.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $44.33 | $41.38 |
| AVG Volume (30 Days) | ★ 1.6M | 148.5K |
| Earning Date | 05-27-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $535,276,000.00 | N/A |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | $22.83 | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $20.05 | $12.04 |
| 52 Week High | $56.00 | $31.44 |
| Indicator | PLAB | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 45.53 |
| Support Level | N/A | $26.32 |
| Resistance Level | $34.71 | $28.96 |
| Average True Range (ATR) | 1.57 | 0.95 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 3.69 | 37.13 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.